Regeneron Pharmaceuticals Inc. (NASDAQ:REGN), along with its development partner Sanofi (SNY), this morning [Mar 6, 2017 | 6:30am] presented some detailed results from the latest study for their breakthrough dermatitis treatment.
Written by StockNews.com
Specifically, the Phase 3 CHRONOS study “showed that patients receiving the investigational drug DUPIXENT with topical corticosteroids achieved significantly improved measures of overall disease severity compared to TCS alone in adults with uncontrolled moderate-to-severe atopic dermatitis.”
The study was conducted over the course of the past year, and the results indicate the drug was highly effective in reducing patient itchiness. See below:
At 52 weeks, the mean percent improvement from baseline in the intensity of patient-reported itch, as measured by the NRS, was 54% for patients who received DUPIXENT weekly with TCS and 56% for patients who received DUPIXENT every two weeks with TCS, compared to 27% for patients receiving placebo with TCS.
If approved, the potential windfall for the new treatment could be huge. Analysts estimate DUPIXENT could be a $4 billion drug for the companies.
Today’s development is a welcome and much-needed piece of good news for the industry. Biotech giants like REGN have largely struggled over the past year, following a historic rally in the sector that came to an abrupt end in early 2016.
Regeneron Pharmaceuticals Inc. shares were unchanged in premarket trading Monday. Year-to-date, REGN has gained 3.15%, versus a 6.66% rise in the benchmark S&P 500 index during the same period.
REGN currently has a StockNews.com POWR Rating of B (Buy), and is ranked #36 of 263 stocks in the Biotech category.
.webp)
Comments
Log in or sign up to join the conversation.